0,1
"6.4	
Summary of evidence and guidelines for stratification of non-muscle-invasive 
bladder cancer",
Recommendations,Strength rating
"Stratify patients into 4 risk groups to predict progression, according to Table 6.1. A patient’s 
risk group can be determined using the 2021 EAU risk group calculator available at  
www.nmibc.net.",Strong
"For information about the risk of disease progression in a patient with primary TaT1 
tumours, not treated with bacillus Calmette-Guérin (BCG), use the data from Table 6.2.",Strong
"Use the 2006 EORTC scoring model to predict the risk of tumour recurrence in individual 
patients not treated with BCG.",Strong
"Use the 2016 EORTC scoring model or the CUETO risk scoring model to predict the risk  
of tumour recurrence in individual patients treated with BCG intravesical immunotherapy 
(the 2016 EORTC model is calculated for 1 to 3 years of maintenance, the CUETO model  
for 5 to 6 months).",Strong
